cloNIDine
| Drug Name | Form | Strength | Non-Formulary | Restricted | TX Sub | Notes |
|---|---|---|---|---|---|---|
| Catapres-TTS-1 | FILM, EXTENDED RELEASE, TRANSDERMAL | 0.1 mg/24 hr | ||||
| Catapres-TTS-2 | FILM, EXTENDED RELEASE, TRANSDERMAL | 0.2 mg/24 hr | ||||
| Catapres-TTS-3 | FILM, EXTENDED RELEASE, TRANSDERMAL | 0.3 mg/24 hr | ||||
| Duraclon | SOLUTION, INTRATHECAL | 1 mg/10 mL | ||||
| Catapres | TABLET, ORAL | 0.1 mg |
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | cloNIDine (Catapres) |
| Criteria 1: Potentially inappropriate medication use in older adults. (Table 2) | |
| Drug(s) | central alpha-agonists for the treatment of hypertension |
| Rationale | High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension. |
| Recommendation | Avoid cloNIDine as first-line treatment for hypertension. |
| Quality of evidence: Low, Strength of Recommendation: Strong | |